NewAmsterdam Pharma Co NV
NAMS
Company Profile
Business description
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
Contact
Gooimeer 2-35
NaardenNH1411 DC
NLDT: +31 352062971
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
68
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,365.70 | 24.70 | 0.30% |
| CAC 40 | 7,593.87 | 38.00 | 0.50% |
| DAX 40 | 22,496.98 | 71.15 | 0.32% |
| Dow JONES (US) | 40,669.36 | 141.74 | 0.35% |
| FTSE 100 | 8,495.76 | 0.91 | 0.01% |
| HKSE | 22,119.41 | 111.30 | 0.51% |
| NASDAQ | 17,446.34 | 14.98 | -0.09% |
| Nikkei 225 | 36,452.30 | 406.92 | 1.13% |
| NZX 50 Index | 12,148.60 | 245.29 | 2.06% |
| S&P 500 | 5,569.06 | 8.23 | 0.15% |
| S&P/ASX 200 | 8,145.60 | 19.40 | 0.24% |
| SSE Composite Index | 3,279.03 | 7.62 | -0.23% |